>Brookings Oregon News, Sports, & Weather | The Curry Coastal Pilot

News Classifieds Web
web powered by Web Search Powered by Google

News arrow News arrow Business arrow Expert: Beauty, recreation can fuel region’s economy

Expert: Beauty, recreation can fuel region’s economy Print E-mail
February 21, 2012 09:14 pm

 

Curry County’s spectacular scenery and outdoor recreation opportunities can be a catalyst to diverse economic growth, according to a development expert.

Ron Fox, executive director of Southern Oregon Regional Economic Development Inc., spoke during the annual Business Outlook Conference in Smith River earlier this month.

 

Many small businesses looking to relocate are drawn to places where employees will enjoy living, Fox said.

“Curry and Del Norte counties just shout out quality of life,” he said, “whether it’s a boat ride on the Rogue River, a walk through the Redwoods or a fishing trip.”

Attracting visitors is often the first step toward having a business relocate in that area, he said.

He gave some examples of small businesses that have set up shop in Southwest Oregon after the owners came to the region as visitors. They include:

•Bauer Fly Reels of Ashland, which manufactures and distributes its $300 to $800 reels worldwide.

•Esquire Piano Inc. of Medford, which restores high-end pianos including some used by Elton John.

•Cary’s of Oregon, which produces toffee in its Grants Pass plant.

•Marzi Sinks of Ashland, whose owners relocated after years of attending the Oregon Shakespeare Festival.

Fox added that broadband Internet access is “very important” to luring new businesses.

Southern Oregon Regional Economic Development Inc. has devised a six-county Southern Oregon marketing team. Curry, Coos, Josephine, Jackson, Klamath and Lake counties are included in the collaborative marketing effort.

“We work diligently to connect with the thousands and thousands of tourists who travel through our area,” Fox said.

More information about Southern Oregon Regional Economic Development Inc. is available at www.soregon.com.

 

Business News by Yahoo Finance

  • China shares lead Asia higher, dollar buoyed
    Asian stocks shrugged off a drop in Wall Street and hovered near three-year highs on Monday, with China taking the lead after data showed a robust jump in profits earned by industrial firms in the world's second-largest economy. The two-day Federal Reserve policy review ending on Wednesday was also in focus but expectations were for Chair Janet Yellen to deliver the usual dovish message.
  • JP Morgan questioned on private bank impropriety: WSJ
    As a result of the questioning regarding potential conflicts of interest, the New York-based bank has sharpened its disclosures to clients, the newspaper said, citing sources. The Office of the Comptroller of the Currency, one of JP Morgan's regulators, has been in discussions with the bank regarding the potential conflicts of interest in recent months, according to the report. "Being transparent is part of our normal course of business and it's what drives our client communications," Darin Oduyoye, a spokesman for JP Morgan's asset-management unit, told Reuters on Sunday. If brokers push clients to buy the in-house brand of financial product, rather than provide impartial financial advice, the bank could stand to benefit at the expense of the client.
  • Pfizer's need for deal looms larger with earnings report
    Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline. While many industry watchers expect Pfizer to re-engage with Britain's AstraZeneca in coming months, some say the U.S. drugmaker should consider targets more focused on biotechnology, a strategy that has paid off for Merck & Co and Bristol-Myers Squibb Co. Although Pfizer is conducting trials of promising products - including breast cancer drug palbociclib and vaccines against meningitis and staph aureus - it needs far more drugs to generate meaningful sales growth, said Ori Hershkovitz, analyst with the Tel Aviv-based Sphera Fund, which holds Pfizer shares.     "Pfizer is in a very desperate spot, having seen most of its pipeline disappoint and facing multiple patent expirations," he said.

Follow Curry Coastal Pilot headlines on Follow Curry Coastal Pilot headlines on Twitter

© Copyright 2001 - 2014 Western Communications, Inc. All rights reserved. By Using this site you agree to our Terms of Use